Northland Securities analyst Carl Byrnes maintained a Buy rating on MiMedx Group (MDXG – Research Report) today and set a price target of $12.00. The company’s shares closed yesterday at $7.76.
Byrnes covers the Healthcare sector, focusing on stocks such as Durect, Oncternal Therapeutics, and MiMedx Group. According to TipRanks, Byrnes has an average return of -8.1% and a 34.11% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for MiMedx Group with a $11.67 average price target.
See Insiders’ Hot Stocks on TipRanks >>
MDXG market cap is currently $903.1M and has a P/E ratio of -314.17.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MDXG in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MiMedx Group (MDXG) Company Description:
MiMedx Group, Inc. is an advanced wound care and an emerging therapeutic biologics company. It engages in developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The company processes the human placental tissue utilizing its proprietary PURION process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx Group was founded on July 30, 1985 and is headquartered in Marietta, GA.
Read More on MDXG:
- MIMEDX Provides AXIOFILL® Update & Reiterates 2023 Full Year Net Sales and Fourth Quarter Adjusted EBITDA Margin Outlook
- MiMedx announces conversion of outstanding Series B convertible preferred stock
- MIMEDX Announces Conversion of Outstanding Series B Convertible Preferred Stock to Common Stock
- Spectral AI appoints Peter Carlson as CFO
- MIMEDX to Participate in Upcoming Investor Conferences
